Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.52 |
| ▸ | POLA1 | P09884 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31685421 | 0.87 | P2RY1 (0.55) | — | |
| SCHEMBL17521209 | 0.86 | PNP (0.58) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL7199411 | 0.85 | PNP (0.62) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL3707304 | 0.85 | PNP (0.62) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL17521212 | 0.85 | PNP (0.62) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL23647921 | 0.85 | PNP (0.62) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL31685306 | 0.85 | P2RY1 (0.57) | — | |
| SCHEMBL31685859 | 0.84 | ADRB1 (0.53) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL31685677 | 0.84 | PNP (0.55) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL31685847 | 0.84 | PNP (0.55) | PNPLMNATP53HTTPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | PNP 135/4885LMNA 240/4885TP53 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.